Chlorin E6-photodynamic therapy basal cell carcinoma
Purpose of the study. Evaluation of the therapeutic efficacy of chlorin E6-photodynamic therapy (PDT) with photosensitizers (PS) photoditazine, photolone and photoran in patients suffering basal cell skin carcinoma.Materials and methods. The efficacy of chlorin E6-PDT was studied in 532 patients wit...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2021-12-01
|
| Series: | Исследования и практика в медицине |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/660 |
| _version_ | 1826559242136453120 |
|---|---|
| author | V. N. Kapinus M. A. Kaplan E. V. Yaroslavtseva-Isayeva I. S. Spichenkova S. A. Ivanov |
| author_facet | V. N. Kapinus M. A. Kaplan E. V. Yaroslavtseva-Isayeva I. S. Spichenkova S. A. Ivanov |
| author_sort | V. N. Kapinus |
| collection | DOAJ |
| description | Purpose of the study. Evaluation of the therapeutic efficacy of chlorin E6-photodynamic therapy (PDT) with photosensitizers (PS) photoditazine, photolone and photoran in patients suffering basal cell skin carcinoma.Materials and methods. The efficacy of chlorin E6-PDT was studied in 532 patients with basal cell skin cancer (BCC) aged 28 to 93 years. PhS Photoditazine was used in 72 (13,5 %) patients at a dose of 0.5-1.0 mg/kg, PhS Photolon - in 281 (52,8 %) patients at a dose of 1.1-1.6 mg/kg and PhS Photoran - in 179 (33,6 %) people at a dose of 1.1-1.6 mg/kg.Sessions of local irradiation of tumor foci were performed on a laser device "Latus-2" (662 nm) with a power density of 200-500 mW/cm2, light energy was applied to the tumors at a dose of 100-300-600 J/cm2.Results. During the follow-up period from 6 months to 5 years, 16.2 % of cases of relapse were diagnosed in the study group. When analyzing the results, it was found that the percentage of relapses was minimal when using all PhS in patients who underwent PDT for the first time established BCC of the initial stages (neoplasms up to 2.0 cm) and amounted to 2.2 % (4 patients out of 183), and with a prevalence of the process of more than 2.0 cm and up to 4.0 cm, 9.5 % (10 patients out of 105) of relapses were found. In the results of treatment of recurrent skin malignancies with PDT using derivatives of chloride E6, depending on the prevalence of the process, a similar trend was observed: with the size of tumor foci up to 2.0 cm, the percentage of repeated relapses was less and amounted to 17.1 % (18 patients out of 105) than in the treatment of neoplasms more than 2.0 cm and up to 4.0 cm (28.8 % of relapses - 21 patients out of 73).Conclusions. Chlorin E6-PDT makes it possible to effectively treat primary and recurrent BCC in an independent variant, and the results of treatment depend on a number of factors, including the prevalence of the disease and the presence or absence of previous treatment. |
| first_indexed | 2024-04-10T01:25:30Z |
| format | Article |
| id | doaj.art-e33332e3128e45d5ad5debae3c39ac03 |
| institution | Directory Open Access Journal |
| issn | 2410-1893 |
| language | Russian |
| last_indexed | 2025-03-14T08:57:16Z |
| publishDate | 2021-12-01 |
| publisher | QUASAR, LLC |
| record_format | Article |
| series | Исследования и практика в медицине |
| spelling | doaj.art-e33332e3128e45d5ad5debae3c39ac032025-03-02T12:44:10ZrusQUASAR, LLCИсследования и практика в медицине2410-18932021-12-0184334310.17709/2410-1893-2021-8-4-3418Chlorin E6-photodynamic therapy basal cell carcinomaV. N. Kapinus0M. A. Kaplan1E. V. Yaroslavtseva-Isayeva2I. S. Spichenkova3S. A. Ivanov4A. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological CenterA. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological CenterA. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological CenterA. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological CenterA. F. Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological Center; National Medical Research Radiological Centre of the Ministry of Health of the Russian FederationPurpose of the study. Evaluation of the therapeutic efficacy of chlorin E6-photodynamic therapy (PDT) with photosensitizers (PS) photoditazine, photolone and photoran in patients suffering basal cell skin carcinoma.Materials and methods. The efficacy of chlorin E6-PDT was studied in 532 patients with basal cell skin cancer (BCC) aged 28 to 93 years. PhS Photoditazine was used in 72 (13,5 %) patients at a dose of 0.5-1.0 mg/kg, PhS Photolon - in 281 (52,8 %) patients at a dose of 1.1-1.6 mg/kg and PhS Photoran - in 179 (33,6 %) people at a dose of 1.1-1.6 mg/kg.Sessions of local irradiation of tumor foci were performed on a laser device "Latus-2" (662 nm) with a power density of 200-500 mW/cm2, light energy was applied to the tumors at a dose of 100-300-600 J/cm2.Results. During the follow-up period from 6 months to 5 years, 16.2 % of cases of relapse were diagnosed in the study group. When analyzing the results, it was found that the percentage of relapses was minimal when using all PhS in patients who underwent PDT for the first time established BCC of the initial stages (neoplasms up to 2.0 cm) and amounted to 2.2 % (4 patients out of 183), and with a prevalence of the process of more than 2.0 cm and up to 4.0 cm, 9.5 % (10 patients out of 105) of relapses were found. In the results of treatment of recurrent skin malignancies with PDT using derivatives of chloride E6, depending on the prevalence of the process, a similar trend was observed: with the size of tumor foci up to 2.0 cm, the percentage of repeated relapses was less and amounted to 17.1 % (18 patients out of 105) than in the treatment of neoplasms more than 2.0 cm and up to 4.0 cm (28.8 % of relapses - 21 patients out of 73).Conclusions. Chlorin E6-PDT makes it possible to effectively treat primary and recurrent BCC in an independent variant, and the results of treatment depend on a number of factors, including the prevalence of the disease and the presence or absence of previous treatment.https://www.rpmj.ru/rpmj/article/view/660photodynamic therapyphotosensitizerchlorin e6photoditazinphotonphotoranbasal cell skin cancer |
| spellingShingle | V. N. Kapinus M. A. Kaplan E. V. Yaroslavtseva-Isayeva I. S. Spichenkova S. A. Ivanov Chlorin E6-photodynamic therapy basal cell carcinoma Исследования и практика в медицине photodynamic therapy photosensitizer chlorin e6 photoditazin photon photoran basal cell skin cancer |
| title | Chlorin E6-photodynamic therapy basal cell carcinoma |
| title_full | Chlorin E6-photodynamic therapy basal cell carcinoma |
| title_fullStr | Chlorin E6-photodynamic therapy basal cell carcinoma |
| title_full_unstemmed | Chlorin E6-photodynamic therapy basal cell carcinoma |
| title_short | Chlorin E6-photodynamic therapy basal cell carcinoma |
| title_sort | chlorin e6 photodynamic therapy basal cell carcinoma |
| topic | photodynamic therapy photosensitizer chlorin e6 photoditazin photon photoran basal cell skin cancer |
| url | https://www.rpmj.ru/rpmj/article/view/660 |
| work_keys_str_mv | AT vnkapinus chlorine6photodynamictherapybasalcellcarcinoma AT makaplan chlorine6photodynamictherapybasalcellcarcinoma AT evyaroslavtsevaisayeva chlorine6photodynamictherapybasalcellcarcinoma AT isspichenkova chlorine6photodynamictherapybasalcellcarcinoma AT saivanov chlorine6photodynamictherapybasalcellcarcinoma |